We tested the hypotheses that NfL concentrations would be raised in individuals with Huntington's disease, would increase as disease progressed, and that concentrations would correlate with disease onset in HTT mutation carriers with premanifest Huntington's disease and with clinical progression in those with manifest disease, therefore acting as an indicator of neurodegeneration. The gene discussed is NEFL; the disease is juvenile Huntington disease.